Developing an HIV cytotoxic T-lymphocyte vaccine: Issues of CD8 T-cell quantity, quality and location

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Abstract. Masopust D (University of Minnesota, Minneapolis, MN, USA). Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location (Review). J Intern Med 2008; 265: 125-137. Issues of quantity, quality and location impact the ability of CD8 T cells to mediate protection from infection. These issues are considered in light of human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) vaccination. Methods are reviewed that result in 100- to 1000-fold higher frequencies of vaccine-specific memory CD8 T cells than that achieved by current HIV/SIV vaccine approaches. Data demonstrating that location within mucosal tissues has a direct impact on memory CD8 T-cell function are discussed. Arguments are made that establishing memory CD8 T cells within mucosal sites of transmission, a priori to natural infection, may be essential for conferring optimal and rapid protection. Lastly, it is proposed that heterologous prime-boost vaccination with recombinant live replicating vectors, which has the potential to induce tremendous numbers of cytolytic memory CD8 T cells within mucosal tissues, would provide a far more stringent test of the hypothesis that memory CD8 T cells could, in principal, form the basis for a preventative HIV vaccine.

Original languageEnglish (US)
Pages (from-to)125-137
Number of pages13
JournalJournal of Internal Medicine
Volume265
Issue number1
DOIs
StatePublished - Jan 2009

Keywords

  • CD8
  • CTL
  • HIV
  • Mucosa
  • Vaccine

Fingerprint Dive into the research topics of 'Developing an HIV cytotoxic T-lymphocyte vaccine: Issues of CD8 T-cell quantity, quality and location'. Together they form a unique fingerprint.

  • Cite this